↓ Skip to main content

A multicentre phase III randomised controlled single-masked clinical trial evaluating the cl inical e fficacy and safety o f light-masks at p reventing dark-a daptation in the tr eatment of ea rly…

Overview of attention for article published in Trials, November 2014
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A multicentre phase III randomised controlled single-masked clinical trial evaluating the cl inical e fficacy and safety o f light-masks at p reventing dark-a daptation in the tr eatment of ea rly diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial
Published in
Trials, November 2014
DOI 10.1186/1745-6215-15-458
Pubmed ID
Authors

Sobha Sivaprasad, Geoffrey Arden, A Toby Prevost, Roxanne Crosby-Nwaobi, Helen Holmes, Joanna Kelly, Caroline Murphy, Gary Rubin, Joanna Vasconcelos, Philip Hykin

Abstract

This study will evaluate hypoxia, as a novel concept in the pathogenesis of diabetic macular oedema (DMO). As the oxygen demand of the eye is maximum during dark-adaptation, we hypothesize that wearing light-masks during sleep will cause regression and prevent the development and progression of DMO. The study protocol comprises both an efficacy and mechanistic evaluation to test this hypothesis.Method/Design: This is a phase III randomised controlled single-masked multicentre clinical trial to test the clinical efficacy of light-masks at preventing dark-adaptation in the treatment of non-central DMO. Three hundred patients with non-centre-involving DMO in at least one eye will be randomised 1:1 to light-masks and control masks (with no light) to be used during sleep at night for a period of 24 months. The primary outcome is regression of non-central oedema by assessing change in the zone of maximal retinal thickness at baseline on optical coherence tomography (SD-OCT). Secondary outcomes will evaluate the prevention of development and progression of DMO by assessing changes in retinal thickness in different regions of the macula, macular volume, refracted visual acuity and level of retinopathy. Safety parameters will include sleep disturbance. Adverse events and measures of compliance will be assessed over 24 months. Participants recruited to the mechanistic sub-study will have additional retinal oximetry, multifocal electroretinography (ERG) and microperimetry to evaluate the role of hypoxia by assessing and comparing changes induced by supplemental oxygen and the light-masks at 12 months.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Unknown 68 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 13%
Researcher 8 12%
Student > Ph. D. Student 6 9%
Student > Bachelor 6 9%
Lecturer 3 4%
Other 14 20%
Unknown 23 33%
Readers by discipline Count As %
Medicine and Dentistry 22 32%
Nursing and Health Professions 5 7%
Neuroscience 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Psychology 2 3%
Other 6 9%
Unknown 26 38%